|1.21||+0.0200||+1.68%||Vol 49.25K||1Y Perf -13.14%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||0.04 3.31%|
|Target Price||9.00||Analyst Rating||Strong Buy 1.00|
|Potential %||643.80||Finscreener Ranking||★★★★ 52.34|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★+ 43.03|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★+ 47.04|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||5.06||Earnings Rating||Strong Sell|
|Market Cap||53.77M||Earnings Date||9th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.12|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||150.19K|
|Avg. Monthly Volume||123.96K|
|Avg. Quarterly Volume||92.03K|
CytoSorbents Corporation (NASDAQ: CTSO) stock closed at 1.21 per share at the end of the most recent trading day (a 1.68% change compared to the prior day closing price) with a volume of 49.25K shares and market capitalization of 53.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 156 people. CytoSorbents Corporation CEO is Phillip P. Chan.
The one-year performance of CytoSorbents Corporation stock is -13.14%, while year-to-date (YTD) performance is -21.94%. CTSO stock has a five-year performance of -88.41%. Its 52-week range is between 1.03 and 4.59, which gives CTSO stock a 52-week price range ratio of 5.06%
CytoSorbents Corporation currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 2.21, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -57.92%, a ROC of -60.46% and a ROE of -83.58%. The company’s profit margin is -91.55%, its EBITDA margin is -105.90%, and its revenue ttm is $21.72 Million , which makes it $0.50 revenue per share.
Of the last four earnings reports from CytoSorbents Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.12 for the next earnings report. CytoSorbents Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for CytoSorbents Corporation is Strong Buy (1), with a target price of $9, which is +643.80% compared to the current price. The earnings rating for CytoSorbents Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
CytoSorbents Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
CytoSorbents Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 24.68, ATR14 : 0.13, CCI20 : -71.42, Chaikin Money Flow : -0.14, MACD : -0.12, Money Flow Index : 20.36, ROC : -3.97, RSI : 40.01, STOCH (14,3) : 37.97, STOCH RSI : 0.16, UO : 53.17, Williams %R : -62.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of CytoSorbents Corporation in the last 12-months were: Al W. Kraus (Option Excercise at a value of $31 800), Bator Michael (Buy at a value of $6 430), Kathleen P. Bloch (Buy at a value of $34 205), Phillip Chan (Option Excercise at a value of $87 840), Phillip P. Chan (Buy at a value of $60 950), Phillip P. Chan (Option Excercise at a value of $87 688), Vincent Capponi (Option Excercise at a value of $57 550)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.